TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Outlook Therapeutics ( (OTLK) ) just unveiled an announcement.
On November 3, 2025, Outlook Therapeutics announced the resubmission of its Biologics License Application for ONS-5010 to the U.S. FDA, following a productive meeting with the agency in September 2025. This step aims to address issues raised in a Complete Response Letter received in August 2025, potentially paving the way for U.S. approval and expanding its market presence in the treatment of wet age-related macular degeneration.
The most recent analyst rating on (OTLK) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Underperform.
Outlook Therapeutics is facing critical financial challenges with no revenue and high leverage, posing substantial risks. The technical analysis shows weak momentum with mixed signals, while the valuation indicates non-profitability. These factors collectively suggest a low stock score.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD.
Average Trading Volume: 3,839,428
Technical Sentiment Signal: Sell
Current Market Cap: $55.97M
For a thorough assessment of OTLK stock, go to TipRanks’ Stock Analysis page.